Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 128 publications
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.
Journal: JCO precision oncology
Published: June 17, 2026
Real-Time Breath Diagnostics: Linking Molecular Pathways, Measurement Technologies, and Clinical Translation.
Journal: International journal of molecular sciences
Published: March 30, 2026
Larotrectinib in Patients With Tumors With NTRK Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E.
Journal: JCO precision oncology
Published: February 20, 2026
TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies.
Journal: Molecular cancer therapeutics
Published: January 06, 2026
Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors.
Journal: Cancer chemotherapy and pharmacology
Published: November 21, 2025
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
Journal: JCO precision oncology
Published: October 30, 2025
Patient Blood Management in Cancer Surgery.
Journal: International anesthesiology clinics
Published: October 30, 2025
Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
Journal: JCO precision oncology
Published: October 09, 2025
Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers.
Journal: Journal for immunotherapy of cancer
Published: October 09, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Journal: JCO precision oncology
Published: August 27, 2025
Targeted therapy combinations with ipatasertib in multi-cell type 3D tumor spheroid models.
Journal: Academia oncology
Published: August 05, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors.
Journal: JCO precision oncology
Published: July 16, 2025
Last Updated: 09/26/2026